Date | Time | Source | Headline | Symbol | Company |
07/22/2024 | 1:00AM | GlobeNewswire Inc. | CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine | EU:VLA | Valneva SE |
07/17/2024 | 4:00PM | GlobeNewswire Inc. | Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion | EU:VLA | Valneva SE |
07/04/2024 | 12:00PM | GlobeNewswire Inc. | Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024 | EU:VLA | Valneva SE |
07/04/2024 | 12:00PM | GlobeNewswire Inc. | Declaration of shares and voting rights - Valneva SE - June 30, 2024 | EU:VLA | Valneva SE |
07/01/2024 | 1:00AM | GlobeNewswire Inc. | Valneva reçoit une autorisation de mise sur le marché en Europe pour le premier vaccin au monde contre le chikungunya, IXCHIQ® | EU:VLA | Valneva SE |
07/01/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® | EU:VLA | Valneva SE |
07/01/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® | EU:VLA | Valneva SE |
06/26/2024 | 11:45AM | GlobeNewswire Inc. | Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale et la nomination d’un nouvel administrateur à son conseil d’administration | EU:VLA | Valneva SE |
06/26/2024 | 11:45AM | GlobeNewswire Inc. | Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board | EU:VLA | Valneva SE |
06/26/2024 | 11:45AM | GlobeNewswire Inc. | Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board | EU:VLA | Valneva SE |
06/24/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® | EU:VLA | Valneva SE |
06/24/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® | EU:VLA | Valneva SE |
06/24/2024 | 1:00AM | GlobeNewswire Inc. | Valneva annonce l’approbation par Santé Canada du premier vaccin au monde contre le chikungunya, IXCHIQ® | EU:VLA | Valneva SE |
06/05/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update | EU:VLA | Valneva SE |
06/05/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update | EU:VLA | Valneva SE |
06/05/2024 | 1:00AM | GlobeNewswire Inc. | Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction | EU:VLA | Valneva SE |
06/04/2024 | 12:00PM | GlobeNewswire Inc. | VALNEVA - Déclaration d’actions et de droits de vote : 31 mai 2024 | EU:VLA | Valneva SE |
06/04/2024 | 12:00PM | GlobeNewswire Inc. | VALNEVA - Declaration of shares and voting rights: May 31, 2024 | EU:VLA | Valneva SE |
06/04/2024 | 11:35AM | GlobeNewswire Inc. | Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June | EU:VLA | Valneva SE |
06/04/2024 | 11:35AM | GlobeNewswire Inc. | Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June | EU:VLA | Valneva SE |
06/04/2024 | 11:35AM | GlobeNewswire Inc. | Valneva annonce sa participation à différentes conférences investisseurs du mois de juin | EU:VLA | Valneva SE |
06/03/2024 | 11:35AM | GlobeNewswire Inc. | Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases | EU:VLA | Valneva SE |
06/03/2024 | 11:35AM | GlobeNewswire Inc. | Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases | EU:VLA | Valneva SE |
06/03/2024 | 11:35AM | GlobeNewswire Inc. | Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious Diseases | EU:VLA | Valneva SE |
05/31/2024 | 11:35AM | GlobeNewswire Inc. | Valneva reçoit un avis positif du CHMP pour une autorisation de mise sur le marché en Europe de son vaccin contre le chikungunya | EU:VLA | Valneva SE |
05/31/2024 | 11:35AM | GlobeNewswire Inc. | Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine | EU:VLA | Valneva SE |
05/31/2024 | 11:35AM | GlobeNewswire Inc. | Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine | EU:VLA | Valneva SE |
05/21/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer | EU:VLA | Valneva SE |
05/21/2024 | 1:00AM | GlobeNewswire Inc. | Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur Scientifique | EU:VLA | Valneva SE |
05/21/2024 | 1:00AM | GlobeNewswire Inc. | Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer | EU:VLA | Valneva SE |